Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abrégé

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

Classes IPC  ?

• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/5355 - Oxazines non condensées contenant d'autres hétérocycles
• A61P 35/00 - Agents anticancéreux
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• C07D 471/04 - Systèmes condensés en ortho
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou

Abrégé

11, R1 and Cy are as defined herein. Herein are disclosed compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving tuberculosis (TB) and/or non-tuberculous mycobacteria (NTM).

Classes IPC  ?

• A61P 31/04 - Agents antibactériens
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• C07D 498/10 - Systèmes condensés en spiro
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou

Abrégé

Herein is provided inter alia, CD20-binding domains and chimeric antigen receptors (CARs), as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, which are particularly useful in the prevention and/or treatment of cancer and/or autoimmune disease.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• C07K 14/725 - Récepteurs de lymphocytes-T

Abrégé

11, R1 and Cy are as defined herein. Herein are disclosed compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving tuberculosis (TB) and/or non-tuberculous mycobacteria (NTM).

Classes IPC  ?

• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• A61P 31/10 - Antifongiques
• C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
• A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

(1) Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. (1) Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. (2) Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abrégé

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention discloses compounds according to Formula I: wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving neurodegenerative disorders by administering the compound of the invention.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Produits et services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical and scientific research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the, examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely, configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; pharmaceutical drug development services Medical services; Medical advisory services; Medical and pharmaceutical consultation; Pharmaceutical advice

Abrégé

The present invention discloses compounds according to Formula (I), wherein G and Cy are as defined herein. Herein are disclosed compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving tuberculosis (TB) and/or non-tuberculous mycobacteria (NTM).

Classes IPC  ?

• C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• A61P 31/10 - Antifongiques
• A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques

Abrégé

11, R1, R2, R3, R4a, R4b, R5, R6, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of proliferative diseases by administering a compound of the invention.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• C07D 213/40 - Atome d'azote substituant acylé
• C07D 213/53 - Atomes d'azote
• C07D 213/55 - AcidesEsters
• C07D 213/56 - Amides
• C07D 213/57 - Nitriles
• C07D 213/64 - Un atome d'oxygène lié en position 2 ou 6
• C07D 213/73 - Radicaux amino ou imino non substitués
• C07D 213/74 - Radicaux amino ou imino substitués par des radicaux hydrocarbonés ou par des radicaux hydrocarbonés substitués
• C07D 237/08 - Composés hétérocycliques contenant des cycles diazine-1, 2 ou diazine-1, 2 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/10 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 411/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 411/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• C07D 471/14 - Systèmes condensés en ortho
• C07D 498/04 - Systèmes condensés en ortho

Abrégé

122, R1, and R2 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12, IL-17 and/or IL-23, respiratory diseases, endocrine diseases, metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering a compound of the invention.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles

Abrégé

The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression

Abrégé

The present invention discloses compounds according to Formula (I), wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R7, R8, R9and R10 are as defined herein. The present invention relates to compounds having α4β7 integrin inhibitory action, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of a disease, disorder or condition that is mediated by α4β7 integrin, by administering the compound of the invention.

Classes IPC  ?

• C07D 213/74 - Radicaux amino ou imino substitués par des radicaux hydrocarbonés ou par des radicaux hydrocarbonés substitués
• C07D 213/84 - Nitriles
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 213/643 - Phénoxy-2 pyridinesLeurs dérivés
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone

Classes IPC  ?

• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61P 17/06 - Antipsoriasiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• C07D 471/04 - Systèmes condensés en ortho

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• C07D 471/04 - Systèmes condensés en ortho

Abrégé

Herein are provided, inter alia, novel compositions and solid forms of compound (I) useful in the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, interferons ("interferonopathies", especially type I or type III interferonopathies), IL-12 and/or IL-23.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• A61P 17/06 - Antipsoriasiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention provides compounds according to Formula (I), wherein R1, R21233 are as defined herein. The present invention also provides methods for the production of such compounds, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL-12 and/or IL-23 by administering the compounds of the invention.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention relates to improved methods for the use of a compound according to formula I in the treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), by contraindicating combined therapy with specific IPF therapeutic compounds, where the combined therapy results in a poorer adverse event profile. The present invention relates to improved methods for the use of a compound according to formula I in the treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), by contraindicating combined therapy with specific IPF therapeutic compounds, where the combined therapy results in a poorer adverse event profile.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abrégé

The present invention discloses compounds according to Formula (I) wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving neurodegenerative disorders by administering the compound of the invention.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C07D 471/04 - Systèmes condensés en ortho

Abrégé

The present invention discloses compounds according to Formula (I) wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving neurodegenerative disorders by administering the compound of the invention.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline

Produits et services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services , namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services Medical services; providing medical and pharmaceutical advice; gene bank services

Produits et services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services Medical services; providing medical and pharmaceutical advice; gene bank services

Produits et services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services Medical services; providing medical and pharmaceutical advice; gene bank services

Abrégé

The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, avoiding, contraindicating or discontinuing concomitant use or co-administration of one or more compounds that are cytochrome P450 (CYP) inhibitors and/or P-gp inhibitors, particularly CYP3A4 inhibitors and/or P-gp inhibitors, and more particularly strong CYP3A4 inhibitors and/or strong P-gp inhibitors.

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 37/02 - Immunomodulateurs
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, avoiding, contraindicating or discontinuing concomitant use or co-administration of one or more compounds that are cytochrome P450 (CYP) inducers and/or P-gp inducers, particularly CYP3A4 inducers and/or P-gp inducers, and more particularly strong CYP3A4 inducers and/or strong P-gp inducers.

Classes IPC  ?

• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification. The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification.

Classes IPC  ?

• C07H 17/08 - Hétérocycles d'au moins huit chaînons, p. ex. érythromycines
• C07H 1/00 - Procédés de préparation des dérivés du sucre

Produits et services

Pharmaceutical substances and preparations for human use; Biopharmaceutical substances and preparations for human use.. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services.. Medical services; Medical and pharmaceutical advisory and consultancy services; Preparing pharmaceuticals for others..

Produits et services

Pharmaceutical substances and preparations for human use; Biopharmaceutical substances and preparations for human use.. Medical, scientific and industrial research services; Pharmaceutical and biopharmaceutical research and development services; The examination and testing of genes; Development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; Development, examination and testing of medicaments; The development of test systems for pharmaceutical and biopharmaceutical products; Development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services.. Medical services; Medical and pharmaceutical advisory and consultancy services; Preparing pharmaceuticals for others..

Produits et services

Pharmaceutical substances and preparations for human use; Biopharmaceutical substances and preparations for human use.. Medical, scientific and industrial research services; Pharmaceutical and biopharmaceutical research and development services; The examination and testing of genes; Development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; Development, examination and testing of medicaments; The development of test systems for pharmaceutical and biopharmaceutical products; Development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services.. Medical services; Medical and pharmaceutical advisory and consultancy services; Preparing pharmaceuticals for others..

Produits et services

Software used as medical monitoring and control tool; software as a medical device [SaMD]; computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; medical apparatus and instrument in the form of a system comprising an automated manufacturing device incorporated with reagents and software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (SaaS) featuring software for medical monitoring and control; providing non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; providing non-downloadable, cloud-based software featuring software for use in medical decision support systems; providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical (product) evaluation services. Medical services; medical and pharmaceutical (product) advisory and consultancy services; cell therapy services; medical services relating to the removal, treatment and processing of human cells.

Produits et services

Software used as medical monitoring and control tool; software as a medical device [samd]; computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; medical apparatus and instrument in the form of a system comprising an automated manufacturing device incorporated with reagents and software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (saas) featuring software for medical monitoring and control; providing non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; providing non-downloadable, cloud-based software featuring software for use in medical decision support systems; providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; providing information about the results of clinical trials; evaluation of pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical (product) evaluation. Medical services; medical and pharmaceutical (product) advisory and consultancy services; cell therapy services; medical services relating to the removal, treatment and processing of human cells.

Produits et services

Software used as medical monitoring and control tool; software as a medical device [samd]; computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; medical apparatus and instrument in the form of a system comprising an automated manufacturing device incorporated with reagents and software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (saas) featuring software for medical monitoring and control; providing non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; providing non-downloadable, cloud-based software featuring software for use in medical decision support systems; providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; providing information about the results of clinical trials; evaluation of pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical (product) evaluation. Medical services; medical and pharmaceutical (product) advisory and consultancy services; cell therapy services; medical services relating to the removal, treatment and processing of human cells.

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use; clinical diagnostic reagents. Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer databanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services; conducting clinical trials; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others; stemcell and celltherapy services; medical services relating to the removal, treatment and processing of human cells.

Produits et services

Pharmaceutical substances and preparations for human use, namely, pharmaceutical preparations and engineered patient T cells for the treatment of cancer; biopharmaceutical substances and preparations for human use, namely, biopharmaceutical preparations and engineered patient T cells for the treatment of cancer; clinical diagnostic reagents for medical use Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals Medical, scientific and industrial research services in the field of pharmaceuticals, engineered patient T-cells, cell therapy, and gene therapy; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression, namely, analysis and testing of cells to determine the presence of particular genes; analysis and testing of cells to determine efficacy for treatment of cancer; development, examination, namely, quality control, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; development of test systems in the nature of testing procedures and protocols, computer software for testing, reagents and testing kits for testing for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer databanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services; scientific research in the nature of conducting clinical trials for others; Providing information about the results of clinical trials for pharmaceutical products; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others being engineered patient T-cells; medical services, namely, Stemcell and celltherapy services; Medical services relating to the removal, treatment and processing of human cells

Abrégé

The present invention relates to new and improved methods for the use of Compound 1 in the treatment of inflammatory diseases and/or diseases associated with hypersecretion of IFNa and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, and pharmaceutical unit dosage compositions comprising compound 1 for use therein.

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 37/02 - Immunomodulateurs
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The present invention relates to new and improved methods for the use of Compound 1 in the treatment of inflammatory diseases and/or diseases associated with hypersecretion of IFNa and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, and pharmaceutical unit dosage compositions comprising compound 1 for use therein.

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 37/02 - Immunomodulateurs
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Produits et services

recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Produits et services

recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Produits et services

recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use; clinical diagnostic reagents. Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer databanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services; conducting clinical trials; Providing information about the results of clinical trials for pharmaceutical products; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others; Stemcell and celltherapy services; Medical services relating to the removal, treatment and processing of human cells.

Produits et services

Software used as medical monitoring and control tool; Software as a medical device [SaMD]; Computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (Saas) featuring software for medical monitoring and control; non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; non-downloadable, cloud-based software featuring software for use in medical decision support systems; Providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical (product) evaluation, advisory and consultancy services; cell therapy services; Medical services relating to the removal, treatment and processing of human cells.

Produits et services

Software used as medical monitoring and control tool; Software as a medical device [SaMD]; Computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (Saas) featuring software for medical monitoring and control; non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; nondownloadable, cloud-based software featuring software for use in medical decision support systems; Providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical (product) evaluation, advisory and consultancy services; cell therapy services; Medical services relating to the removal, treatment and processing of human cells.

Produits et services

Software used as medical monitoring and control tool; Software as a medical device [SaMD]; Computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (Saas) featuring software for medical monitoring and control; non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; non-downloadable, cloud-based software featuring software for use in medical decision support systems; Providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical (product) evaluation, advisory and consultancy services; cell therapy services; Medical services relating to the removal, treatment and processing of human cells.

Abrégé

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, R2, and Cy are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• C07D 471/04 - Systèmes condensés en ortho
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Classes IPC  ?

• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique

Abrégé

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• C07D 471/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to solid forms of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and to pharmaceutical preparations comprising them and methods of their manufacture, as well as the use of said solid forms or preparations for the prophylaxis and/or treatment of inflammatory conditions, muscular disease, fibrotic diseases, viral infection, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis, especially osteoarthritis.

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques

Abrégé

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The present invention relates to solid forms of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and to pharmaceutical preparations comprising them and methods of their manufacture, as well as the use of said solid forms or preparations for the prophylaxis and/or treatment of inflammatory conditions, muscular disease, fibrotic diseases, viral infection, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis, especially osteoarthritis.

Classes IPC  ?

• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette

Abrégé

The present invention discloses compounds according to Formula (I): Wherein R1, R2, R3a, R3b, R41233, and the subscript n are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering a compound of the invention.

Classes IPC  ?

• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to improved methods for the use of a compound according to formula I in the treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), by contraindicating combined therapy with specific IPF therapeutic compounds, where the combined therapy results in a poorer adverse event profile.

Classes IPC  ?

• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of endocrine, nutritional, metabolic, and/or cardiovascular diseases by administering the compound of the invention.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho

Abrégé

The present invention discloses compounds according to Formula (I) wherein R1, R2, R3123 3 are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering a compound of the invention.

Classes IPC  ?

• C07D 217/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 471/04 - Systèmes condensés en ortho
• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux

Abrégé

EZEE)-oxime of formula (I), its pharmaceutically acceptable salts and purification.

Classes IPC  ?

• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine

Produits et services

Pharmaceutical preparations.

Abrégé

The present invention discloses compounds according to Formula I, wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, pain, and/or abnormal angiogenesis associated diseases by administering the compounds of the invention.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• C07D 471/04 - Systèmes condensés en ortho
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention discloses compounds according to Formula (I) wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

Classes IPC  ?

• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Abrégé

The present invention discloses compounds according to Formula (I), wherein R1a, R1b, R1c, R2a121233, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

Classes IPC  ?

• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• C07D 471/04 - Systèmes condensés en ortho
• C07D 487/04 - Systèmes condensés en ortho
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention discloses compounds according to Formula (I), wherein R1, R2a122, Y and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

Classes IPC  ?

• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• C07D 471/04 - Systèmes condensés en ortho
• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline

Abrégé

The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Classes IPC  ?

• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The present invention discloses compounds according to Formula (I), wherein X, G, R1, R2a, R2b, R3, R4, and R5 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving hepatitis B by administering the compound of the invention.

Classes IPC  ?

• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• C07D 495/04 - Systèmes condensés en ortho
• A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine

Produits et services

Pharmaceutical preparations.

Abrégé

The present invention discloses compounds according to Formula I: (l) Wherein R1is as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of that may be useful in the prophylaxis and/or treatment of polycystic kidney disease (PKD), by administering the compound of the invention.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61K 31/155 - Amidines (), p. ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole

Abrégé

The present invention discloses compounds according to Formula (I): (I). Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
• A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon

Abrégé

The present invention discloses compounds according to Formula I, wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole

Abrégé

The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
• A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p. ex. foscarnet, trichlorfon

Produits et services

Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith Medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields; development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; gene bank services

Produits et services

Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith Medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields; development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; gene bank services

Abrégé

The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of endocrine, nutritional, metabolic, and/or cardiovascular diseases by administering the compound of the invention.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 5/00 - Médicaments pour le traitement des troubles du système endocrinien
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline

Abrégé

The invention discloses compounds of Formula (I), 4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Classes IPC  ?

• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07C 311/45 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso au moins un des atomes d'azote, liés par des liaisons simples, faisant partie de l'un des groupes X étant un hétéro-atome, Y étant un atome quelconque, p. ex. N-acylaminosulfonamides
• C07D 213/30 - Atomes d'oxygène
• C07D 213/64 - Un atome d'oxygène lié en position 2 ou 6
• C07D 213/71 - Atomes de soufre auxquels est lié un second hétéro-atome
• C07D 215/36 - Atomes de soufre
• C07D 231/56 - BenzopyrazolesBenzopyrazoles hydrogénés
• C07D 235/28 - Atomes de soufre
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• C07D 471/04 - Systèmes condensés en ortho

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computerdatabanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Produits et services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computerdatabanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abrégé

The present invention relates to improved methods of administering compound 1 therapy, involving increased effectiveness of compound 1 by avoiding or contraindicating combined CYP3A4/P-gp inducers, e.g. rifampicin.

Classes IPC  ?

• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine

Abrégé

The present disclosure describes high concentration liquid formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, at least 80mM of a buffering agent and at least 80mM of a stabilizer. In addition, the present disclosure is related to pharmaceutical formulations of an anti-IL-17C antibody and provides methods of making and methods of using such formulations.

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention discloses compounds according to Formula I: wherein R1, R2a, X, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• C07D 471/04 - Systèmes condensés en ortho
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.

Classes IPC  ?

• A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
• A61P 17/06 - Antipsoriasiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses

Abrégé

The present invention provides for compounds of formula (I) 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The invention discloses compounds of Formula (I) wherein R1, R2, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Classes IPC  ?

• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
• C07D 407/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to the use of an antibody or antibody fragment specific for IL-17C in the prophylaxis and/or treatment of autoimmune skin diseases. In one embodiment, the antibody or antibody fragment specific for IL-17C comprises a HCDR1 region of amino acid sequence SEQ ID NO: 7, a HCDR2 region of amino acid sequence SEQ ID NO: 8, a HCDR3 region of amino acid sequence of SEQ ID NO: 9, a LCDR1 region of amino acid sequence SEQ ID NO: 13, a LCDR2 region of amino acid sequence of SEQ ID NO: 14 and a LCDR3 region of amino acid sequence SEQ ID NO: 15. In another embodiment, the antibody or antibody fragment specific for IL-17C comprises a variable heavy chain of SEQ ID NO: 17 and a variable light chain of SEQ ID NO: 16. In some embodiments the autoimmune skin disease is selected from pemphigus vulgaris, bullous pemphigoid, vasculitis, pyoderma gangrenosum and Sweet's disease.

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons

Abrégé

The present invention discloses compounds according to Formula (I), wherein R1, R2a, R2b, R3, R4, and R5 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving hepatitis B by administering the compound of the invention.

Classes IPC  ?

• C07D 491/052 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à six chaînons
• A61P 31/20 - Antiviraux pour le traitement des virus ADN
• A61P 31/12 - Antiviraux
• A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine

Abrégé

The present invention discloses compounds according to Formula (I): wherein R1, R2, R3a, R3b1233, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNFα, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

Classes IPC  ?

• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The present invention relates to compounds useful in the prophylaxis and/or treatment of one or more fibrotic diseases. In particular, the compounds of the invention antagonize GPR84, a G-protein-coupled receptor. The present invention also provides pharmaceutical compositions comprising the compounds for use and methods for the prophylaxis and/or treatment of one or more fibrotic diseases by administering said compound.

Classes IPC  ?

• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention discloses compounds according to Formula I: (Formula I) Wherein R111, R222, R3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles

Abrégé

The present invention discloses compounds according to Formula I: (Formula I) Wherein $R^1$, $L_1$, $R^2$, $L_2$, $R^3$, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, au- toimmune diseases, proliferative diseases, transplantation rejection, diseases involving impair- ment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• C07D 471/04 - Systèmes condensés en ortho